Navigation Links
MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
Date:9/10/2009

est discomfort (one percent) or chest pain (0 percent), were rare and comparable to placebo. There were no decreases in lung function, as measured by spirometry, between the active and placebo groups.

"These sub-analyses further heighten our enthusiasm for LEVADEX and its potential to help the many patients who suffer from the debilitating effects of migraine, including the potential to provide benefit to a number of significant subpopulations of migraine patients who are not well served by currently available therapies," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "We look forward to continuing development of LEVADEX and initiating a confirmatory Phase 3 trial in the first quarter of 2010."

LEVADEX data are being presented in a late-breaking oral platform presentation titled "LEVADEX(TM), a novel orally inhaled treatment for acute migraine: efficacy and tolerability results of a Phase 3 study" on Saturday, September 12, 2009 at the 14th Congress of the International Headache Society in Philadelphia, PA by clinical trial investigator Stephen Silberstein, M.D., F.A.C.P., director of the Jefferson Headache Center, and professor in the Department of Neurology at Jefferson Medical College of Thomas Jefferson University. In addition, three poster presentations titled 1) "Efficacy and tolerability of MAP0004, a novel inhaled therapy, in treating acute migraine", 2) "Efficacy evaluation of LEVADEX(TM) (previously MAP0004) in treating resistant migraine including migraine with allodynia, migraine treated late in its cycle, morning migraine and disabling migraine" and 3) "Efficacy evaluation of LEVADEX(TM) (previously MAP0004) in treating a broad spectrum of acute migraine attacks including patients using triptans and patients not using triptans" will be available for review at the conference.

Webcast Information

MAP Pharmaceuticals will host a webcast on
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... In the latest call for gender equity ... than 60 doctors and leading medical experts from across ... Food and Drug Administration,s (FDA) decision to approve 26 ... sexual dysfunction compared with ZERO for women,s most common ... women by approving the first-ever drug to treat Hypoactive ...
(Date:8/1/2014)... DALLAS , August 1, 2014 ... Care Market by Type (Traditional Wound Closure, Anti infective), ... Active (Artificial Skin & Skin Substitutes), Pressure Relief ... by MarketsandMarkets, the global Wound Care Market is expected ... Billion in 2014, growing at a CAGR of ...
(Date:8/1/2014)... PLYMOUTH MEETING, Pa. , Aug. 1, 2014 /PRNewswire/ ... that it will host a conference call to report ... 11, 2014 at 9:00 AM ET. CEO Dr. ... will discuss second quarter earnings, provide a corporate ... The update will include clinical development plans for VGX-3100, ...
Breaking Medicine Technology:60+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3
... , CHANGCHUN, China and LOS ... Bulletin Board: CYXN) ("Yongxin" or,"the Company"), a leading pharmaceutical ... the third quarter ended,September 30, 2009. , ... products depend on discretionary,spending, we expect as the economy ...
... , MINNEAPOLIS, Dec. 10 Uroplasty, Inc. ... that develops, manufactures and markets innovative proprietary products to ... the OrBIT Trial of its Urgent® PC Neuromodulation System ... edition of THE JOURNAL OF UROLOGY® . The ...
Cached Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4
(Date:8/1/2014)... (PRWEB) August 01, 2014 Hot off the ... destination spa category of the World’s Best Awards by ... a month-long celebration of National Relaxation Day (technically August 15). ... series of MAJOR experts to help guests celebrate relaxation throughout ... it is for health and wellness to carve out time ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, ... a time-honored destination for a good cut and conversation. ... be the spot to tackle an often overlooked health concern: ... partnership, the U.S. Centers for Disease Control and Prevention, together ... help of barbershop staff to both discuss and diagnose high ...
(Date:8/1/2014)... 2014 For years, proponents have praised ... study conducted by the Ohio State University, ... behind in terms of their health and development, raising ... best for their baby. So does this new research ... Steven Shapiro , chair of Pediatrics at Abington Memorial ...
(Date:8/1/2014)... GlobalDatas new report, "United ... provides key market data on the United ... value, in millions of US dollars, volume ... dollars) within market segments - Electrosurgical RF ... Plasma Coagulation Generators. , To view the ...
(Date:8/1/2014)... -- Women who serve in the U.S. military are ... a new study suggests. Overall, members of the ... researchers found that women respond differently to their experience ... to concerns about sexual harassment or being treated unfairly, ... sexual assault, both within and outside the military, and ...
Breaking Medicine News(10 mins):Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 2Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 3Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 2Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 3Health News:Women in Military Drink Less Than Civilians, Report Shows 2
... of the most aggressive cancers worldwide and its incidence is ... infection and aflatoxin contamination of foodstuffs. The cancer is also ... and China have been studying gene activity in liver tumors ... of detecting tumors that spread. They found that there is ...
... born during night time have a higher risk of ... day time. Previous studies have also shown that infants ... an increased risk of death at birth, urging the ... obstetric and neonatal care during the night. Researchers conducted ...
... been believed, over the years, to be a potential cure against ... true by researchers who have studied changes in immune cells' response ... 12 healthy subjects who took one gram of vitamin C a ... in all of them during the period. Their finding(in two patients) ...
... from The Forsyth Institute in Boston and the University of ... of the Journal of Microbiology that bad breath or halitosis ... back portion of the top of your tongue. The study ... the tongues of those with halitosis and those with fresh ...
... of the long-running Framingham Heart Study have now found ... levels of homocysteine, an amino acid whose build-up has ... and dementia, increases the risk of developing congestive heart ... age 72 years, who were studied during 1979 to ...
... researchers in the Journal of Hypertension indicates that ... improve their atherosclerotic risk profile by consuming alcohol ... serum lipoprotein(a), a powerful predictor of organ damage, ... studied 402 patients with untreated essential hypertension to ...
Cached Medicine News:Health News:Germs to blame for bad breath 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: